Compare STOK & SLVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | SLVM |
|---|---|---|
| Founded | 2014 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2019 | 2021 |
| Metric | STOK | SLVM |
|---|---|---|
| Price | $36.13 | $45.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $36.10 | ★ $54.00 |
| AVG Volume (30 Days) | ★ 560.9K | 327.7K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 3.89% |
| EPS Growth | ★ 30.67 | N/A |
| EPS | 0.85 | ★ 3.24 |
| Revenue | $36,555,000.00 | ★ $3,351,000,000.00 |
| Revenue This Year | $430.19 | $0.21 |
| Revenue Next Year | N/A | $2.62 |
| P/E Ratio | $42.08 | ★ $14.27 |
| Revenue Growth | ★ 316.34 | N/A |
| 52 Week Low | $5.35 | $37.52 |
| 52 Week High | $38.62 | $73.73 |
| Indicator | STOK | SLVM |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 39.33 |
| Support Level | $30.50 | $39.43 |
| Resistance Level | $37.98 | $48.98 |
| Average True Range (ATR) | 2.04 | 2.61 |
| MACD | 0.41 | -0.52 |
| Stochastic Oscillator | 77.87 | 13.01 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.